Notably, the high prevalence of p53-psi or TP53 exon-6 truncating mutations in certain tumors also suggests that this class of TP53 mutations represents a strong precision medicine candidate target comparable to the well-documented EGFR, ROS and ALK mutations in NSCLC (Korpanty et al., 2014). This evidence concerns the gene TP53 and non-small cell lung carcinoma.